LRG1 promotes atherosclerosis by activating macrophages

Wang, J.; Zhang, S.; Zhong, J.; Liu, H.; Li, W.; Chen, M.; Xu, L.; Zhang, W.; Zhang, Z.; Wei, Z.; Guo, J.; Wang, X.; Sui, J.; Liu, X.

doi:10.1101/2024.01.23.576507

bioRxiv · 10.1101/2024.01.23.576507

LRG1 promotes atherosclerosis by activating macrophages

Wang, J.·Zhang, S.·Zhong, J.·Liu, H.·Li, W.·Chen, M.·Xu, L.·Zhang, W.·Zhang, Z.·Wei, Z.·Guo, J.·Wang, X.·Sui, J.·Liu, X.

View original source ↗Export metadata ↓

Abstract

BackgroundAtherosclerosis is a chronic inflammatory disease of the arterial wall characterized by the accumulation of cholesterol-rich lipoproteins in macrophages. Leucine-rich alpha-2 glycoprotein 1 (LRG1) is a circulating protein associated with inflammation, however, its role in atherosclerosis remains unclear. This study identified its role in macrophage pro-inflammatory differentiation and revealed the relationship between LRG1 and atherosclerosis. MethodWe evaluated the impact of LRG1 on atherosclerosis progression by analyzing atherosclerotic tissue and serum samples from patients with coronary artery disease (CAD) and healthy individuals and analyzed its role in such a process using two types of mice models: Apoe knock-out mice (Apoe-/-) and Apoe and Lrg1 double knock-out mice (Apoe-/-/Lrg1-/-). These mice were fed with a high-fat diet for 16 to 32 weeks to simulate conditions exacerbating atherosclerosis. To examine the effects of inhibiting LRG1 on atherogenesis, we administered intraperitoneal injections of LRG1 neutralizing antibody (50g/kg) weekly to Apoe-/- mice for 8 weeks. We conducted in vitro assays using bone marrow-derived macrophages isolated from wild-type mice and analyzed transcriptional signatures using RNA sequencing. Additionally, we utilized small molecular inhibitors to validate the signaling pathway through which LRG1 promotes macrophage-driven inflammation. ResultsLRG1 levels were found to be elevated in patients with atherosclerosis and correlated with higher levels of a plasma pro-inflammatory biomarker high-sensitive C-reactive protein (hsCRP), and several macrophage-related pro-inflammatory markers including CD68, VE-Cadherin and VCAM-1. In a high fat diet induced Apoe-/- mouse atherosclerosis model, the deletion of LRG1 gene significantly delayed atherogenesis progression and reduced levels of macrophage-related pro-inflammatory cytokines. Addition of purified LRG1 to cultured macrophages stimulated those macrophages to pro-inflammatory M1-like polarization regulated by the activation of ERK and JNK pathways. An anti-LRG1 neutralizing antibody effectively blocked LRG1-induced macrophage M1-like polarization in vitro and conferred therapeutic benefits to animals with ApoE deficiency-induced atherosclerosis. ConclusionLRG1 plays an important pro-inflammatory role in atherosclerosis by influencing macrophage polarization towards a pro-inflammatory state. The inhibition of LRG1 with neutralizing antibodies may offer a potential therapeutic strategy for patients with atherosclerosis by mitigating the pro-inflammatory response and delaying disease progression, offering a novel therapy in atherosclerosis management. Translational PerspectiveAtherosclerosis, a persistent inflammatory condition affecting the arterial wall, serves as the underlying pathophysiological basis for acute ischemic cardiovascular events. The involvement of macrophages is crucial in the advancement of atherosclerosis. In this investigation, heightened levels of plasma LRG1 were observed in individuals with coronary artery disease. Moreover, this study presents initial evidence highlighting LRG1 as a pivotal activator of macrophages, instigating a pro-inflammatory M1 polarization during atherogenesis through the activation of ERK1/2 and JNK pathways. The use of an anti-LRG1 neutralizing antibody demonstrated a delay in atherosclerosis progression in an animal model, suggesting a potential therapeutic target for atherosclerosis treatment. Suppression of LRG1 production could impede atherosclerosis advancement and enhance plaque stability. Utilizing neutralizing antibodies against LRG1 emerges as a promising therapeutic approach for treating atherosclerosis.

Explore related subjects

pathology Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Wang, J., Zhang, S., Zhong, J., Liu, H., Li, W., Chen, M., Xu, L., Zhang, W., Zhang, Z., Wei, Z., Guo, J., Wang, X., Sui, J., Liu, X.. 2024-01-25. LRG1 promotes atherosclerosis by activating macrophages. https://doi.org/10.1101/2024.01.23.576507

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Dysregulated Platelet GPIb alpha - VWF Signalling in Abdominal Aortic Aneurysm formation and Progression

Background: Platelets are critical drivers of thrombo-inflammatory responses in different cardiovascular diseases. Abdominal aortic aneurysm (AAA) is a progressive, life-threatening vascular disorder mainly characterised by chronic inflammation, extracellular matrix degradation, and the formation of a platelet-rich intraluminal thrombus (ILT). Experimental and clinical evidence identified platelets as main players in AAA pathology as evidenced by elevated platelet activation and procoagulant activity that critically contribute to AAA progression. Methods: The present study investigated the contribution of glycoprotein (GP)Ib alpha, the von Willebrand factor (VWF)-binding subunit of the platelet GPIb-IX-V complex, to AAA initiation and progression in experimental AAA using the ePPE mouse model and in patients. Results: Genetic ablation of platelet GPIb alpha significantly attenuated early aneurysm expansion in experimental AAA, indicating a critical role for GPIb alpha during the initial stages of aneurysm development. This initial effect was compensated at later time points showing no differences in aneurysm progression between groups. Notably, genetic deletion of GPIb alpha induced a constitutively hyperactive platelet phenotype already in naive mice that was further amplified during experimental AAA. This elevated platelet hyperactivity was mainly due to increased GPVI activation of platelets 28 days post-surgery. To assess the clinical relevance, spatial profiles of human ILT specimens from patients with AAA were analysed. In the ILT, we detected a highly compartmentalised distribution of GPIb alpha and VWF with pronounced enrichment within the luminal layer. In parallel, circulating VWF activity as well as platelet surface expression of GPIb alpha were significantly increased in patients with AAA. Conclusion: Collectively, these findings identify a dysregulated GPIb alpha-VWF axis in human AAA pathology, mainly characterised by enhanced platelet GPIb alpha surface expression and increased activity of circulating VWF.

pathology↗

bioRxiv2026

OmiCoreTumorDetector: an open, molecularly validated model for mapping tumour regions in colorectal cancer H&E sections

Defining tumour regions on haematoxylin and eosin (H&E) sections is a routine first step in spatial-omics studies, yet it is usually done by hand and is difficult to reproduce. We present OmiCoreTumorDetector, an openly licensed model that maps tumour-enriched regions in colorectal cancer (CRC) H&E sections and exports them as QuPath-compatible annotations. The released model (omicore-tumordetector-crc-he-v0.1) is an ensemble of three convolutional classifiers trained on 100,000 public tissue tiles, combined with Macenko stain normalisation at inference. During development we found that the main obstacle to reuse was calibration under stain-domain shift rather than discrimination: a single model kept an area under the ROC curve (AUROC) of 0.955 on unseen slides while its sensitivity at the conventional 0.5 threshold fell to 0.48. Training on non-normalised tiles raised tumour AUROC on an independently collected tile set from 0.836 to 0.992, and normalising at inference reduced false-positive tumour area in normal-adjacent tissue by 16- to 26-fold. On five 10x Visium HD CRC sections that share no material with the training data, the released model called 27.7-48.5% of tissue as tumour in three carcinoma sections and 0.08% and 1.82% in two normal-adjacent sections, exporting no tumour region from either normal section. On the carcinoma section with matched single-cell-resolution transcriptomics, agreement with transcriptome-derived tumour-cell identities reached an AUROC of 0.985 (95% spatial-block bootstrap CI 0.975-0.993). The image model never observes gene expression, so this is orthogonal evidence. The model localises tumour-enriched regions at 112 um resolution; it does not identify individual malignant cells and has not yet been validated across scanners, institutions or histological variants. Code, weights and evaluation are released under Apache-2.0 and installable with pip install omicoretumordetector.

pathology↗

bioRxiv2026

Thyroid Dysfunction in Male Patients at Asia Med Laboratory, Herat, Afghanistan July 2021-Jan 2022

Objective: Hyperthyroidism and hypothyroidism related to iodine deficiency are major public health concerns in Afghanistan. This study aimed to assess the frequency of thyroid dysfunction among male patients referred for thyroid testing and its association with age, and to examine monthly trends in thyroid dysfunction at Asia Med Laboratory in Herat, Afghanistan, from July 2021 to January 2022. Methods: A retrospective analysis was conducted on 250 male patients aged 0-69 years. We measured Serum TSH, total T4, and total T3 levels, and thyroid status was classified using age specific reference ranges. In addition, the frequency of thyroid dysfunction was analyzed across age groups with monthly trends of thyroid state. Results: Overall, the euthyroid state consisted of 69.2% of participants, 24.8% with overt hypothyroidism, 3.2% with overt hyperthyroidism, and 2.8% with subclinical hyperthyroidism. Thyroid status differed significantly by age (p = 0.0135), with hypothyroidism increasing in older age groups and reaching its highest proportion among men aged 60-69 years (55.6%). Euthyroidism predominated in patients aged 10-39 years, while hyperthyroidism across age groups remained relatively infrequent. After September 2021, a threefold increase was observed in the total number of male patients referred for thyroid testing. During this period, the proportion of hyperthyroidism increased slightly, whereas hypothyroidism cases declined. Conclusion: In conclusion, hypothyroidism was more frequent with older age. The rise in absolute case numbers after September 2021 likely reflects increased patient referrals, underscoring the need for ongoing monitoring of thyroid function. The study may assist in the early management of thyroid disorders and in reducing their complications.

pathology↗